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Background:We evaluated the pathological complete response (pCR) rate after neoadjuvant epirubicin, (E)
cyclophosphamide (C) and docetaxel containing chemotherapy with and without the addition of bevacizumab in patients
with triple-negative breast cancer (TNBC).
Patients and methods: Patients with untreated cT1c-4d TNBC represented a stratiﬁed subset of the 1948
participants of the HER2-negative part of the GeparQuinto trial. Patients were randomized to receive four cycles EC (90/
600 mg/m2; q3w) followed by four cycles docetaxel (100 mg/m2; q3w) each with or without bevacizumab (15 mg/kg;
q3w) added to chemotherapy.
Results: TNBC patients were randomized to chemotherapy without (n = 340) or with bevacizumab (n = 323). pCR (ypT0
ypN0, primary end point) rates were 27.9% without and 39.3% with bevacizumab (P = 0.003). According to other pCR
deﬁnitions, the addition of bevacizumab increased the pCR rate from 30.9% to 41.8% (ypT0 ypN0/+; P = 0.004), 36.2%
to 46.4% (ypT0/is ypN0/+; P = 0.009) and 32.9% to 43.3% (ypT0/is ypN0; P = 0.007). Bevacizumab treatment [OR 1.73,
95% conﬁdence interval (CI) 1.23–2.42; P = 0.002], lower tumor stage (OR 2.38, 95% CI 1.24–4.54; P = 0.009) and
grade 3 tumors (OR 1.68, 95% CI 1.14–2.48; P = 0.009) were conﬁrmed as independent predictors of higher pCR in
multivariate logistic regression analysis.
Conclusions: The addition of bevacizumab to chemotherapy in TNBC signiﬁcantly increases pCR rates.
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introduction
Patients with triple-negative breast cancer (TNBC) are at
highest risk of relapse and death among all breast cancer
subtypes [1]. At present, anthracycline–taxane-based
chemotherapy represents the standard of care for TNBC
patients, as no speciﬁc treatments are available for this
heterogeneous disease. TNBC is highly proliferative, with an
enhanced angiogenesis, high intratumoral vascular endothelial
growth factor (VEGF) levels and activation of genes involved in
angiogenesis [2–5]. Therefore, anti-angiogenic drugs may be
particularly effective. Bevacizumab, a monoclonal antibody
directed against the VEGF-A ligand, has shown clinical efﬁcacy
in patients with metastatic TNBC [6, 7].
In the GeparQuinto study, we have shown that addition of
bevacizumab to neoadjuvant chemotherapy signiﬁcantly
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increased the pCR rate in HER2-negative early-stage breast
cancer [8]. The most notable and pronounced pCR rate was
seen in the TNBC subgroup. Moreover, TNBC is the subtype
with the greatest difference in disease-free and overall survival in
patients with and without pCR after neoadjuvant chemotherapy
[9–11].
Figure 1. Consort statement.
Table 1. Baseline characteristics of all TNBC patients who started therapy
Parameter Statistic EC-D (N = 340) n (%) ECB-DB (N = 323) n (%) Overall, n (%) P-value
Age (years) Mean 48 48 48 0.936
Min, max 28, 75 21, 75 21, 75
Tumor size (mm) by palpation Mean 41.4 41.6 41.5 0.577
Min, max 10.0, 70.0 10.0, 190.0 10.0, 190.0
Tumor size (mm) by sonography Mean 31.3 31.2 31.3 0.865
Min, max 9.0, 167.0 11.0, 100.0 9.0, 167.0
cT cT1-2 286 (84.4) 271 (84.2) 557 (84.3) 0.720
cT3-4a-c 26 (7.7) 21 (6.5) 47 (7.1)
cT4d 27 (8.0) 30 (9.3) 57 (8.6)
Missing 1 1 2
cN Negative 140 (42.8) 132 (42.0) 272 (42.4) 0.873
Positive 187 (57.2) 182 (58.0) 369 (57.6)
Missing 13 9 22
Grading G1 3 (0.9) 4 (1.2) 7 (1.1) 0.851
G2 91 (27.0) 91 (28.2) 182 (27.6)
G3 243 (72.1) 228 (70.6) 471 (71.4)
Missing 3 0 3
Histological tumor type Ductal 291 (85.8) 282 (87.6) 573 (86.7) 0.629
Lobular 10 (2.9) 6 (1.9) 16 (2.4)
Other 38 (11.2) 34 (10.6) 72 (10.9)
Missing 1 1 2
ER/PgR Strictly negativea 305 (89.7) 293 (90.7) 598 (90.2) 0.696
aER/PgR = 0%.
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The GeparQuinto trial was designed to compare the pCR
rates in patients with HER2-negative primary breast cancer. A
secondary objective was to analyze the effect of bevacizumab in
the predeﬁned and stratiﬁed subgroup of TNBC patients.
patients andmethods
objectives
The primary objective of this study was to compare the pCR rates (no
invasive and no noninvasive residuals in breast and lymph nodes; ypT0
ypN0) after neoadjuvant chemotherapy ± bevacizumab among predeﬁned
patients with TNBC. Secondary end point was pCR according to different
deﬁnitions, i.e. ypT0/Tis ypN0; ypT0/Tis ypN0/+; and ypT0 ypN0/+ (no
invasive and no in situ residuals in breast, irrespective of nodal status after
therapy) [12–14]. Further secondary end points were the evaluation of
response rates of breast tumors and axillary nodes assessed by clinical
examination and imaging (breast ultrasound, mammography or magnetic
resonance imaging) after therapy and before surgery, the rate of breast
conservation and compliance.
patients
Women with previously untreated, unilateral or bilateral, primary invasive
breast carcinoma were enrolled in the GeparQuinto study after written
informed consent [8]. Breast cancer diagnosis had to be conﬁrmed
histologically by a core biopsy. TNBC was deﬁned as no HER2
overexpression (Dako-HercepTest: score 0 or 1+, in score 2 no gene
ampliﬁcation by in situ hybridization) and hormone receptor (HR)
expression (estrogen and progesterone receptor <10%) by
immunohistochemistry as assessed by the local pathology. Tumors without
any HR expression (estrogen and progesterone receptor 0%) were deﬁned as
strictly triple-negative. Inclusion and exclusion criteria have been reported
recently [8].
treatment
All patients received epirubicin (E, 90 mg/m2) plus cyclophosphamide (C,
600 mg/m2), both administered on day 1, every 3 weeks for four cycles,
followed by four cycles of docetaxel (D, 100 mg/m2) on day 1, every 3 weeks.
Patients were randomly assigned to receive either eight cycles of
bevacizumab (B, 15 mg/kg body weight) intravenously every 3 weeks starting
on day 1 of the ﬁrst EC cycle (ECB-DB) or no additional treatment (EC-D).
Patients showing neither clinical nor sonographical response (<50%
tumor size reduction) after four cycles of EC ± B were classiﬁed as
nonresponders and were analyzed as having no pCR. These patients were
taken off the initial treatment plan and were randomized within
nonresponder arm (Setting II) to weekly paclitaxel ± the mTOR inhibitor
RAD001 (everolimus, 10 mg/day orally) [15].
Table 2. Efﬁcacy of treatment according to histological, surgical and clinical outcome
Parameter Category EC-D (N = 340) n (%) ECB-DB (N = 323) n (%) Overall, n (%) P-value
pCR breast and nodes (primary end point), RG5, ypT0ypN0
All patients included No 245 (72.1) 196 (60.7) 441 (66.5) 0.003
Yes 95 (27.9) 127 (39.3) 222 (33.5)
95% CI (23.2%, 33.0%) (34.0%, 44.9%)
All included patients, including pCR achieved in setting II No 242 (71.2) 191 (59.1) 433 (65.3) 0.001
Yes 98 (28.8) 132 (40.9) 230 (34.7)
95% CI (24.1%, 34.0%) (35.5%, 46.4%)
Strictly negative patients No 217 (71.1) 176 (60.1) 393 (65.7) 0.006
Yes 88 (28.9) 117 (39.9) 205 (34.3)
95% CI (23.8%, 34.3%) (34.3%, 45.8%)
pCR breast, RG5+4, ypT0 ypN0/+ No 235 (69.1) 188 (58.2) 423 (63.8) 0.004
Yes 105 (30.9) 135 (41.8) 240 (36.2)
95% CI (26.0%, 36.1%) (36.4%, 47.4%)
pCR invasive, RG5+4+3, ypT0/is ypN0/+ No 217 (63.8) 173 (53.6) 390 (58.8) 0.009
Yes 123 (36.2) 150 (46.4) 273 (41.2)
95% CI (31.1%, 41.5%) (40.9%, 52.0%)
pCR invasive breast and nodes, RG5+3, ypT0/is ypN0 No 228 (67.1) 183 (56.7) 411 (62.0) 0.007
Yes 112 (32.9) 140 (43.3) 252 (38.0)
95% CI (28.0%, 38.2%) (37.9%, 48.9%)
Clinical response after EC ± B CR 29 (8.5) 39 (12.2) 68 (10.3)
PR 230 (67.6) 233 (73.0) 463 (70.3)
ORes (CR+PR) 259 (76.2) 272 (85.3) 531 (80.6) 0.004
95% CI for ORes (71.3%, 80.6%) (80.9%, 89.0%)
Missing 0 4 4
Clinical response at surgery CR 94 (27.6) 102 (31.8) 196 (29.7)
PR 180 (52.9) 178 (55.5) 358 (54.2)
ORes (CR+PR) 274 (80.6) 280 (87.2) 554 (83.8) 0.026
95% CI for ORes (76.0%, 84.7%) (83.1%, 90.7%)
Missing 0 2 2
Breast-conserving surgery No 79 (25.1) 85 (28.1) 164 (26.6) 0.441
Yes 236 (74.9) 217 (71.9) 453 (73.4)
Missing 25 21 46
95% CI (69.8%, 79.6%) (66.4%, 76.9%)
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In cases of tumor progression, the study treatment was discontinued and
further local or systemic treatment was permitted at the investigator’s
discretion. Patients could undergo surgery at least 28 days after the last
chemotherapy ± bevacizumab.
assessment of end points
The breast tumor and regional lymph nodes were examined by palpation
at every cycle and by sonographic examination after every second cycle;
breast ultrasound, clinical examination and mammography were carried
out before breast surgery. Clinical complete response was deﬁned
according to WHO criteria [16]. Pathological response in the breast and of
axillary lymph nodes was assessed by the local pathologist according to
modiﬁed Sinn criteria [17]. Pathological reports were reviewed centrally by
a breast oncologist and a pathologist who were blinded to treatment
assignments, and response was staged according to the tumor–node–
metastasis system [18]. Patients were considered to have breast-conserving
surgery (BCS) if the ﬁnal surgical procedure was tumorectomy,
segmentectomy or quadrantectomy.
statistical analysis
Statistical details of the GeparQuinto study have been published recently [8].
All patients who received at least one cycle of chemotherapy ± bevacizumab
were included in the efﬁcacy and safety analyses (Figure 1). Missing data on
response were counted as no response. Multivariate logistic regression
analysis was used to adjust for baseline factors. Univariate logistic regression
was carried out in subgroups; a Breslow–Day test was used for testing the
homogeneity of odds ratios (OR) across subgroups. All statistical analyses
were carried out using SAS software, version 9.2.
results
patients
From November 2007 to June 2010, a subgroup of 678 patients
with TNBC was randomized, 663 of whom started treatments
(intent-to-treat population). The baseline characteristics of the
patients were balanced between both arms (Table 1).
Figure 2. Forrest plot multivariate analysis for pCR in the TNBC cohort.
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efﬁcacy
A total of 95 (27.9%; 95% conﬁdence interval [CI] 23.2–33.0)
patients who received EC-D and 127 (39.3%; 95% CI 34.0–44.9)
treated with ECB-DB had a pCR (ypT0 ypN0; P = 0.003;
Table 2). The pathological response rates according to other
deﬁnitions are shown in Table 2.
The overall clinical response rate (complete and partial
response), determined by palpation and imaging, was
signiﬁcantly higher in the bevacizumab group after four cycles
of EC (76.2% versus 85.3%; P = 0.004) and before surgery
(80.6% versus 87.2%; P = 0.026) compared with no
bevacizumab.
The rate of BCS was identical between patients treated
without or with bevacizumab: (EC-D: 74.9% and ECB-DB:
71.9%; P = 0.441). In patients with strictly negative tumors, this
rate was 74.3% (EC-D) and 72.2% (ECB-DB; P = 0.636).
An analysis adjusted by age, tumor and nodal stage,
histological type and grade revealed an increase in pCR rate
for the addition of bevacizumab to EC-D (OR 1.73, 95% CI
1.23–2.52; P = 0.002). Additionally, lower tumor stage (OR
2.38, 95% CI 1.24–4.54; P = 0.009) and grade 3 tumors (OR
1.68, 95% CI 1.14–2.48; P = 0.009) were conﬁrmed as
independent predictors of higher pCR rates (Figure 2). The
increase in pCR rate with the addition of bevacizumab was
consistent across subgroups (Figure 3), except for cT4 tumors.
Breslow–Day test for interaction was not signiﬁcant for all
subgroup parameters, including clinical tumor stage
(P = 0.081).
Figure 3. Forrest plot on pCR rates (ypT0 ypN0) after chemotherapy without or with bevacizumab in various subgroups of patients with TNBC.
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compliance and safety proﬁle
Of the 663 patients who started treatment, 330 (97.1%) ﬁnished
four cycles EC and 320 (99.1%) four cycles ECB. No change in
tumor size was seen in 20.1% (n = 71; EC) and in 14.1% (n = 45;
ECB) of patients. All these patients, except 12 (EC: n = 4; ECB:
n = 8), were randomized into setting II. Treatment with four
cycles of docetaxel in the remaining responders was ﬁnished by
229 (67.4%; EC-D) and 237 (73.4%; ECB-DB) patients.
Fourteen patients discontinued bevacizumab therapy alone due
to adverse events, patient’s wish or investigator`s advice
(Figure 1).
Chemotherapy was delayed in 35.7% (EC-D) and 45.6%
(ECB-DB) of patients; the dose was reduced in 12.4% and 19.7%
of patients, respectively.
As expected, the safety proﬁle of bevacizumab in TNBC
patients was similar to that in the overall population treated in
GeparQuinto (data not shown) [8].
discussion
Our study shows that the addition of bevacizumab to
neoadjuvant anthracycline–taxane-containing chemotherapy
signiﬁcantly increased the pCR rate (ypT0 ypN0) from 27.9% to
39.3% in patients with operable or locally advanced TNBC
independent of different pCR deﬁnitions. The magnitude of the
differences in pCR rates were the same when alternative TNBC
deﬁnitions were considered. In TNBC, the pCR rate is an
important surrogate marker concerning prognosis [9–11].
When this randomized trial started in 2007, patients with
<10% of tumor cells stained positive for HRs were classiﬁed as
HR-negative [19]. The new classiﬁcation, considering tumors
with ≤1% positively stained tumor cells, was recommended
after the end of the GeparQuinto recruitment [20,21].
In contrast to our results, the NSABP B-40 study did not
show a beneﬁt in the TNBC subgroup of 490 patients by adding
bevacizumab to anthracycline–taxane-based neoadjuvant
chemotherapy [12]. The reasons for these divergent results have
been discussed in detail previously [8]. To summarize, these
results might be attributed to the smaller sample size of TNBC
in the NSABP B-40 compared with our study, the exclusion of
patients with T4a-d carcinomas in NSABP B-40, which
corresponded to 12% of our TNBC cohort; the inclusion of
patients with HR-positive, HER2-negative and node-negative
tumors in NSABP B-40, who were excluded in GeparQuinto.
Patients with lack of response after four EC ± B were considered
nonresponders and excluded from the following taxane-based
therapy; however, only 18 of these nonresponders had a pCR
and did not relevantly change the pCR rate in the total
population. Also, the sequence anthracycline-containing
regimen followed by docetaxel in our study was reversed in the
NSABP study. Moreover, the NSABP B-40 study tested the
additive effect of two antimetabolites using a 2-by-3 factorial
design and therefore applied a decreased dose of docetaxel (75
mg/m2) in the experimental arms. Bevacizumab was
administered during the ﬁrst six chemotherapy cycles only.
By adjusting the analysis for subgroups, the addition of
bevacizumab, lower tumor stage and grade 3 were conﬁrmed as
predictors of a higher pCR rate in TNBC. There are several
strengths and limitations of our study. The multicenter
GeparQuinto trial prospectively stratiﬁed for the TNBC and
represents the largest TNBC cohort with neoadjuvant
chemotherapy and bevacizumab. The results were consistent
even when using other pCR deﬁnitions, and when the
nonresponding patients after four EC+B were included. The
deﬁnition of TNBC (<10% versus <1% ER-positivity) did not
inﬂuence the results. The results from further conﬁrmatory
study in TNBC like GeparSixto (NCT00567554; recruitment
ﬁnished) or CALGB 40603 (NCT00861705, recruitment
ﬁnished) trials should be awaited. The recently presented phase
III BEATRICE study (NCT00528567) could not ﬁnd a beneﬁt
for 3-year-invasive disease-free survival for adjuvant treatment
with bevacizumab in resected TNBC [22].
In vitro and in vivo data, suggesting that cessation of
bevacizumab will stimulate tumor growth, have yet to be
conﬁrmed in metastatic breast cancer [23]. Based on preclinical
models, the concern is that anti-angiogenic agents might
stimulate cancer stem cells by generating intratumoral hypoxia,
and might increase invasive and metastatic properties of breast
cancer cells, impairing patient outcome [24]. A proposed phase
III trial to test the suitability of VEGF-A as a biomarker for
effectiveness of bevacizumab in breast cancer seems to be a step
in the right direction [25].
In conclusion, the addition of bevacizumab to anthracycline–
taxane-based chemotherapy in TNBC increased the pCR rate
signiﬁcantly. It has to be awaited if the observed increase in pCR
rate is large enough to translate into a survival beneﬁt [26],
especially in the light of the negative results of the BEATRICE
study.
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